|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.00 SAR | +0.45% |
|
-0.60% | +5.37% |
| 02-13 | Nahdi Medical Dispenses Dose of Growth |  |
| 11-18 | Kepler Cheuvreux Reduces Nahdi Medical's PT, Affirms Buy Rating | MT |
| Capitalization | 12.94B 3.45B 2.91B 2.65B 2.53B 4.7B 313B 4.88B 30.85B 12.25B 151B 12.68B 528B | P/E ratio 2025 * |
15.8x | P/E ratio 2026 * | 14.8x |
|---|---|---|---|---|---|
| Enterprise value | 14.18B 3.78B 3.19B 2.91B 2.77B 5.15B 342B 5.35B 33.8B 13.42B 165B 13.89B 578B | EV / Sales 2025 * |
1.4x | EV / Sales 2026 * | 1.26x |
| Free-Float |
36.92% | Yield 2025 * |
5.45% | Yield 2026 * | 5.71% |
| 1 day | +0.55% | ||
| 1 week | -0.60% | ||
| Current month | +1.57% | ||
| 1 month | +7.81% | ||
| 3 months | -7.91% | ||
| 6 months | -12.96% | ||
| Current year | +5.37% |
| 1 week | 98.4 |  | 102 |
| 1 month | 91 | | 102.3 |
| Current year | 91 | | 102.3 |
| 1 year | 91 | | 132.1 |
| 3 years | 91 | | 190 |
| 5 years | 91 | | 209.4 |
| 10 years | 91 | | 209.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Yasser Joharji
CEO | Chief Executive Officer | 55 | 01/01/2014 |
| Director of Finance/CFO | 52 | - | |
Khalid Tadlaoui
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/01/2011 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 01/01/2021 | |
| Director/Board Member | 73 | 01/01/2021 | |
Junaid Bajwa
BRD | Director/Board Member | 47 | 01/01/2021 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.45% | -0.60% | -15.31% | -46.76% | 3.45B | |
| +0.50% | +1.94% | +82.45% | +4.33% | 24.75B | |
| -0.16% | +1.15% | +35.01% | +0.82% | 12.76B | |
| +1.42% | +4.45% | +24.39% | +28.86% | 7.16B | |
| -0.02% | -0.83% | -7.58% | +19.11% | 4.75B | |
| -1.69% | -3.14% | -2.17% | -27.65% | 4.28B | |
| -1.44% | -2.14% | +29.69% | -35.90% | 3.17B | |
| -0.52% | +1.40% | -6.87% | +51.35% | 2.93B | |
| +0.94% | -1.24% | +69.42% | - | 2.12B | |
| -0.80% | +0.19% | +6.62% | +19.86% | 1.94B | |
| Average | -0.12% | +0.24% | +21.56% | +1.56% | 6.73B | |
| Weighted average by Cap. | +0.14% | +1.10% | +41.57% | +3.23% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 10.16B 2.71B 2.28B 2.08B 1.99B 3.69B 245B 3.83B 24.21B 9.61B 118B 9.95B 414B | 11.09B 2.96B 2.49B 2.27B 2.17B 4.03B 268B 4.19B 26.44B 10.5B 129B 10.86B 452B |
| Net income | 820M 219M 184M 168M 160M 298M 19.8B 309M 1.95B 776M 9.56B 803M 33.41B | 878M 234M 197M 180M 172M 319M 21.19B 331M 2.09B 830M 10.23B 859M 35.77B |
| Net Debt | 1.24B 330M 278M 254M 242M 450M 29.89B 467M 2.95B 1.17B 14.44B 1.21B 50.45B | 1.03B 273M 230M 210M 201M 372M 24.77B 387M 2.44B 970M 11.96B 1B 41.81B |
Employees
6,182
Sector
Drug Retailers
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/02/26 | 100.00 ﷼ | +0.45% | 71,331 |
| 12/02/26 | 99.55 ﷼ | -0.10% | 232,858 |
| 11/02/26 | 99.65 ﷼ | -0.94% | 111,304 |
| 10/02/26 | 100.60 ﷼ | -0.10% | 120,645 |
| 09/02/26 | 100.70 ﷼ | 0.00% | 125,613 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
99.55SAR
Average target price
131.28SAR
Spread / Average Target
+31.87%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4164 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition